A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
A Triple-Blind, Randomized, Efficacy and Tolerability Comparison Study of PDFE-2304 Topical Solution Versus Minoxidil 5% Topical Solution for the Treatment of Androgenic Alopecia (AGA).
In the register
The register attaches this trial to PDFE-2304 (Neopili) (PDFE Pharma Innovations), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Phase 2
- Sponsor
- PDFE Pharma Innovations FZCO
- Participants (registry)
- 15
- Start
- May 2025
- Primary completion
- August 2025
- Study completion
- September 2025
- Last registry update
- June 2025
- Countries
- India
Conditions studied: Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
Interventions: Minoxidil 5% Topical Solution, PDFE-2304 Topical Solution
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.